1. Introduction

Tissue engineering is an emerging branch of biotechnology and regenerative medicine that combines cells, biomaterials, biological scaffolds, and engineering techniques to repair, replace, or regenerate damaged human tissues and organs.

In Morocco, tissue engineering has significant potential in clinical applications such as:

Skin regeneration for burn victims.

Cartilage and bone reconstruction.

Stem-cell-based tissue repair.

Corneal and ocular surface reconstruction.

Artificial skin and wound-healing technologies.

Regenerative treatments for cardiovascular diseases.

Laboratory-grown tissues for reconstructive surgery.

The clinical application of tissue engineering raises important legal questions concerning patient safety, clinical-trial authorization, professional responsibility, informed consent, product quality, biological material handling, and compensation for medical injuries.

An important legal distinction: Morocco does not have a single comprehensive statute specifically regulating all tissue-engineered products as a separate category. Their regulation must therefore be examined through the country's existing pharmaceutical, medical-practice, biomedical research, public-health, and product-safety frameworks.

2. Legal Framework Governing Tissue Engineering in Morocco

The principal legal framework consists of the following legislation.

A. Law No. 16-98 on Donation, Removal and Transplantation of Human Organs and Tissues

Law No. 16-98, promulgated by Dahir No. 1-99-208 of 25 August 1999, is an important part of Morocco's legal framework for human tissue procurement and transplantation.

Its relevance to tissue engineering includes:

Regulation of human tissue donation and procurement.

Protection of donors against coercion and exploitation.

Requirements concerning consent to tissue donation.

Regulation of authorized transplantation establishments.

Oversight of the preservation, transportation and transplantation of human tissues.

Article 10 provides for formal expression of donor consent before the competent judicial authority, with medical assistance in explaining the implications of donation.

The law was subsequently supplemented by Law No. 26-05 and Law No. 109-13. Morocco also adopted Ministerial Order No. 2250-09 of 18 August 2009, establishing good practices for procurement, transplantation, preservation and transportation of human organs and tissues.

sante.gov.ma+2

Legal significance: Where a tissue-engineered treatment involves donated human tissues or cells falling within the statutory scope of Law No. 16-98, the requirements concerning donation, consent and authorized institutions become particularly important.

However, not every engineered tissue product automatically qualifies as an organ or tissue transplant under this legislation. The legal classification of cultured cells, cellular constructs and synthetic scaffolds must be examined individually.

B. Law No. 28-13 on Biomedical Research

Law No. 28-13 of 2015 is one of the most important laws for clinical research involving tissue-engineered products.

It establishes safeguards for people participating in biomedical research.

Its principal requirements include:

Respect for human dignity and physical integrity.

Voluntary participation in research.

Free, informed and express consent.

The right to withdraw from research.

Ethical examination of research proposals.

Scientific justification and assessment of foreseeable risks.

Monitoring of participants and adverse events.

Articles 3 and 4 establish fundamental consent and human-protection principles.

Article 17 provides for regional committees responsible for reviewing biomedical research proposals and their ethical aspects.

Article 26 requires authorization by the competent government authority for interventional biomedical research.

Article 27 establishes conditions for authorization, including a favourable ethics committee opinion, scientific justification and an acceptable risk assessment.

Article 34 is especially important because it makes the sponsor responsible for damage affecting a participant's health where a causal relationship with the research is established. It also provides for full compensation.

Articles 35–37 address participant monitoring, serious adverse-event reporting and notification of incidents to the competent authorities.

Ma Loi

Legal significance: A clinical investigation involving engineered skin, cartilage, bone or other biological constructs cannot simply be treated as an ordinary medical procedure if it constitutes biomedical research. The requirements of Law No. 28-13 must be considered before the research begins.

C. Law No. 17-04 on the Code of Medicines and Pharmacy

Law No. 17-04, promulgated by Dahir No. 1-06-151 of 22 November 2006, regulates medicines and pharmaceutical activities.

It becomes relevant where a tissue-engineered product is legally classified as a medicinal product or involves a regulated pharmaceutical preparation.

Its regulatory significance includes:

Pharmaceutical product quality.

Manufacturing and distribution controls.

Safety and efficacy requirements.

Pharmaceutical establishment regulation.

Marketing authorization where applicable.

Oversight of medicinal preparations.

A cell-based or tissue-engineered product should not automatically be assumed to be a medicine. Its composition, intended therapeutic purpose, manufacturing process and legal classification determine the applicable regulatory route.

sante.gov.ma+1

D. Law No. 84-12 on Medical Devices

Law No. 84-12 regulates medical devices in Morocco, with its implementing framework including Decree No. 2-14-607 of 18 September 2014.

It may apply to components of tissue-engineering treatments, including:

Artificial scaffolds.

Biomaterial implants.

Regenerative surgical devices.

Tissue-support structures.

Certain engineered materials intended for medical use.

Article 40 of Law No. 28-13 specifically addresses clinical investigations of medical devices. It requires experimental devices to be designed and manufactured so that their use does not compromise participant health and safety, and requires compliance with applicable manufacturing good practices.

sante.gov.ma+1

E. Law No. 131-13 on the Practice of Medicine

Law No. 131-13, promulgated in 2015, regulates medical practice and the operation of private medical establishments.

It is relevant because tissue-engineering procedures involve specialized medical interventions that must be conducted by appropriately qualified professionals in legally authorized establishments.

The regulatory framework covers:

Professional authorization.

Clinical establishment licensing.

Medical professional responsibilities.

Institutional standards.

Compliance with professional and ethical obligations.

The General Secretariat of Government identifies Law No. 131-13 and its implementing Decree No. 2-15-447 as the principal texts governing medical practice and the authorization of clinics.

SGG+1

3. Special Regulation of Cell-Based and Tissue-Engineered Therapies

One of the most significant developments in Morocco occurred on 6 June 2019.

On that date, the Ministry of Health announced restrictions on cell-therapy activities.

According to the Ministry's official announcement:

The collection, processing and administration of autologous cell-therapy preparations for therapeutic or research purposes are restricted to public or private university hospital centres authorized by the Ministry.

Authorization follows consultation with the Human Organ Transplantation Advisory Council.

Patient informed consent is required before collection and administration.

The establishment's preparation, preservation and therapeutic indications must be evaluated against good-practice requirements.

The Ministry expressly connected these activities with Law No. 16-98 and Law No. 28-13.

sante.gov.ma+1

Important regulatory development

This 2019 ministerial announcement is particularly important for tissue engineering because it demonstrates that Morocco does not treat every cell-based regenerative treatment as an unrestricted private medical service.

For example, a clinic proposing to collect a patient's cells, expand or process them in a laboratory and re-administer them for tissue regeneration must consider the applicable authorization requirements.

The restriction is particularly relevant to autologous cell preparations. It should not be interpreted as automatically establishing the precise legal status of every allogeneic, acellular or synthetic tissue-engineered product.

4. Clinical Trial Authorization and Ethical Approval

Clinical application of tissue-engineered products frequently requires scientific investigation before routine therapeutic use.

Under Law No. 28-13, a clinical investigation must satisfy relevant ethical and regulatory requirements.

The process generally involves the following stages:

Stage 1: Scientific justification

Researchers must provide scientific evidence supporting the proposed treatment. This may include laboratory studies, preclinical testing, biocompatibility studies and toxicity assessments.

Stage 2: Research protocol

The sponsor and investigator must prepare a detailed protocol describing:

Research objectives.

Patient-selection criteria.

Tissue procurement methods.

Cell-processing procedures.

Biomaterial composition.

Dosage or implantation methods.

Risk-management arrangements.

Follow-up procedures.

Stage 3: Ethics committee review

The competent regional biomedical research protection committee examines the research proposal, particularly its ethical acceptability.

Stage 4: Regulatory authorization

Interventional biomedical research must obtain authorization from the competent government authority under Article 26.

Stage 5: Informed consent

Participants must receive understandable information about the experimental nature of the treatment, potential risks, anticipated benefits and available alternatives.

Stage 6: Safety monitoring

Researchers must monitor adverse events, treatment outcomes and long-term complications.

Stage 7: Compensation

Where a participant suffers research-related damage and the required causal connection is established, Article 34 imposes compensation responsibilities on the sponsor.

Ma Loi

5. Regulation of Tissue Procurement, Processing and Preservation

Tissue engineering depends on the quality and safety of biological materials.

The regulatory framework must therefore address the entire biological-material lifecycle.

Ministerial Order No. 2250-09 is particularly relevant to the handling and transportation of human tissues within its scope.

The 2019 cell-therapy restrictions also emphasize evaluation of preparation and preservation procedures before authorization.

sante.gov.ma+1

6. Informed Consent and Patient Rights

Informed consent is a central legal requirement in tissue-engineering clinical applications.

A patient must understand that regenerative medicine may involve experimental procedures, uncertain outcomes and risks that differ from conventional surgery.

The consent process should explain:

The origin of the biological material.

Whether the treatment uses autologous or donated cells.

Whether the tissue construct is experimental.

Possible immune reactions.

Infection and contamination risks.

Potential failure of tissue integration.

Possibility of additional surgery.

Long-term monitoring requirements.

Alternatives to the proposed treatment.

Financial and compensation arrangements.

Under Articles 3–5 of Law No. 28-13, consent must be voluntary, informed and express in the biomedical research context.

Consent is not a substitute for regulatory authorization. Even where a patient agrees to experimental treatment, the healthcare establishment must independently satisfy the applicable legal requirements.

Ma Loi+1

7. Medical Liability and Compensation for Tissue-Engineering Injuries

Tissue engineering creates complex liability questions because injuries may arise from medical treatment, laboratory processing, defective biomaterials or institutional failures.

Moroccan liability can be examined through the general principles of the Dahir of Obligations and Contracts (DOC).

A. Article 77 – Liability for Harmful Acts

Article 77 provides the basis for liability where a person's act directly causes damage to another.

For example, a surgeon may face liability if negligent implantation of an engineered tissue construct causes serious injury.

B. Article 78 – Fault-Based Liability

Article 78 addresses fault resulting from an act or omission that directly causes damage.

Potential examples include:

Failure to follow appropriate surgical procedures.

Improper tissue preparation.

Failure to maintain sterile laboratory conditions.

Negligent preservation of biological materials.

Failure to monitor foreseeable complications.

C. Article 79 – Liability of Public Authorities

Article 79 provides a basis for responsibility of the State and public bodies for damage caused by the operation of their services or faults of their agents.

This may become relevant when tissue-engineering treatment takes place in a public university hospital and an institutional service failure causes injury.

AvocAffaire

D. Liability of Research Sponsors

Article 34 of Law No. 28-13 establishes a specific compensation framework for research-related injuries.

This is particularly important when a patient suffers injury during a clinical investigation involving:

Engineered skin grafts.

Experimental cartilage implants.

Stem-cell-derived tissues.

Bioengineered bone substitutes.

Regenerative cellular preparations.

The sponsor's responsibility under this provision is based on proof of the causal relationship between the research and the damage.

E. Manufacturer and Laboratory Liability

Where a defective scaffold, contaminated cell preparation or improperly manufactured medical product causes injury, the manufacturer or relevant laboratory may also face liability under the applicable contractual, civil, pharmaceutical or medical-device rules.

The precise defendant and legal basis depend on who controlled the relevant stage of the process and the classification of the product.

8. Case Laws and Judicial Principles

An important research limitation must be recognized: publicly identifiable Moroccan judgments specifically addressing tissue-engineered implants, laboratory-grown human tissues or regenerative tissue products are not readily established in the available published material.

Accordingly, the following Moroccan medical-liability decisions are relevant by analogy. They should not be misrepresented as direct tissue-engineering judgments.

Case 1: Moroccan Court of Cassation – 20 April 2010

Court: Court of Cassation, Morocco.

Decision No.: 1795.

Case No.: 129/1/3/2008.

Subject: Medical negligence and joint responsibility of a doctor and clinic.

Facts: A patient underwent an emergency hysterectomy. The medical team allegedly failed to ensure that adequate blood supplies were available despite foreseeable haemorrhage risks.

Judicial principle: Medical professionals must take appropriate precautions against foreseeable complications. Healthcare institutions may also be responsible where organizational deficiencies contribute to patient injury.

Application to tissue engineering: A hospital that performs tissue-engineering procedures must maintain appropriate laboratory facilities, qualified personnel, sterilization systems and emergency arrangements.

A failure to provide these safeguards may create institutional as well as professional liability.

Law Gratis

Case 2: Casablanca Court of Appeal – 24 March 2008

Court: Casablanca Court of Appeal.

Decision Nos.: 1550–1551.

Case Nos.: 4009/05–2225/06.

Subject: Medical negligence and the obligation of means.

Facts: A patient sought compensation for alleged medical negligence. The judicial medical expert did not identify a technical error or breach of professional standards.

Judicial principle: A medical professional is generally subject to an obligation of means rather than an absolute guarantee of recovery. A poor treatment outcome does not automatically establish negligence.

Application to tissue engineering: Failure of an engineered cartilage implant or skin graft does not automatically establish medical malpractice.

The court would need to consider whether the healthcare professionals followed appropriate scientific and medical standards, whether the product was defective, and whether the failure resulted from a legally attributable fault.

Law Gratis

Case 3: Moroccan Court of Cassation – 31 May 2001

Court: Court of Cassation, Morocco.

Decision No.: 2149.

Case No.: 1081/1/5/2000.

Subject: Emergency treatment and patient consent.

Judicial principle: Medical necessity may be relevant when assessing circumstances in which treatment proceeds without prior consent.

Application to tissue engineering: This principle may be relevant where an emergency requires immediate surgical intervention. However, it does not authorize routine administration of experimental tissue-engineering products without the required consent and regulatory approvals.

Law Gratis+1

Case 4: Moroccan Court of Cassation – 30 September 2009

Court: Court of Cassation, Morocco.

Decision No.: 3355.

Case No.: 1631/1/3/2007.

Subject: Medical negligence and causal connection.

Judicial principle: The existence of injury after medical intervention does not automatically prove that the intervention caused the injury through negligence. A direct causal connection must be established.

Application to tissue engineering: Suppose a patient develops inflammation after receiving a bioengineered skin graft. Medical experts may need to determine whether the injury resulted from:

The patient's underlying condition.

An immune response.

Contamination during laboratory processing.

A defective biomaterial.

Surgical negligence.

Inadequate post-operative monitoring.

The legal responsibility depends on the proven cause and the applicable liability regime.

Law Gratis

Case 5: Moroccan Court of Cassation – 4 May 2005

Court: Court of Cassation, Morocco.

Decision No.: 1327.

Case No.: 530/1/3/2004.

Subject: Medical liability insurance and third-party compensation.

Facts: A patient suffered paralysis following surgery and brought proceedings involving the doctor, clinic and insurer.

Judicial principle: The decision recognized the possibility of a patient relying on an insurance arrangement intended to provide protection to injured third parties.

Application to tissue engineering: Where a regenerative medicine procedure causes injury, professional indemnity and institutional insurance may become important sources of compensation, subject to policy terms and applicable law.

Law Gratis

Research qualification: These case identifiers are reported in a secondary legal compilation. They should be checked against the original Moroccan judgments before being used as verified judicial authorities in a court filing or academic publication. They are medical-liability analogies, not precedents specifically interpreting tissue-engineering legislation.

9. Comparative International Case Law

International judicial decisions can help explain the legal principles that may become relevant to Moroccan tissue-engineering regulation. They are persuasive comparative materials, not binding Moroccan precedents.

A. Moore v. Regents of the University of California (1990)

Court: Supreme Court of California, United States.

Citation: 51 Cal. 3d 120 (1990).

Facts: John Moore's cells were used to develop a commercially valuable cell line without his knowledge and informed consent.

Judicial significance: The court recognized the importance of disclosure of physicians' financial interests and conflicts of interest. It did not recognize a conversion property claim over the excised cells.

Relevance to Morocco: The case illustrates the importance of transparency when human tissues and cells are collected for research, commercial development or regenerative therapies.

Moroccan researchers and healthcare providers should ensure that consent documents clearly explain relevant research purposes and commercial interests.

B. Sidaway v. Board of Governors of the Bethlem Royal Hospital (1985)

Court: House of Lords, United Kingdom.

Citation: [1985] AC 871.

Judicial significance: The decision addressed the doctor's duty to disclose material risks associated with medical treatment.

Relevance to Morocco: Tissue-engineering procedures may involve uncertain long-term risks, making meaningful patient disclosure and informed consent essential.

This historical decision should be read alongside modern informed-consent standards.

C. Chester v. Afshar (2004)

Court: House of Lords, United Kingdom.

Citation: [2004] UKHL 41.

Facts: A patient underwent surgery without adequate warning of a small but serious risk.

Judicial significance: The court considered the relationship between failure to warn and causation.

Relevance to Morocco: The case demonstrates why a failure to disclose risks in experimental regenerative medicine can create significant legal consequences.

10. Regulation of Clinical Establishments and Professional Qualifications

Tissue-engineering treatment requires cooperation among surgeons, cell biologists, laboratory specialists, pharmacists and other healthcare professionals.

Moroccan Law No. 131-13 and its implementing regulations provide the framework for medical practice and clinical establishments.

The regulatory system should ensure:

Properly qualified medical practitioners.

Authorized clinical establishments.

Appropriate laboratory infrastructure.

Suitable biological-material handling procedures.

Medical supervision during implantation.

Documented patient follow-up.

Compliance with professional ethics.

A medical clinic cannot assume that ordinary authorization to perform surgery automatically authorizes every specialized cellular-therapy activity.

The Ministry's 2019 announcement specifically establishes an additional authorization requirement for the covered autologous cell-therapy activities.

SGG+1

11. Protection of Genetic and Biological Information

Tissue-engineering research may involve sensitive patient information, including:

Genetic profiles.

Stem-cell characteristics.

Tissue compatibility information.

Medical histories.

Cellular test results.

Biological sample identifiers.

Morocco's Law No. 09-08 on the protection of individuals with regard to personal-data processing is relevant to the handling of identifiable patient information.

Healthcare institutions and research sponsors should consider lawful processing, confidentiality, appropriate security measures and applicable requirements for international transfers.

This is particularly important where Moroccan laboratories collaborate with foreign biotechnology companies or conduct international clinical research.

IRC

12. Recent Regulatory Developments and Institutional Oversight

Morocco's regulatory approach has increasingly emphasized the quality and traceability of clinical research.

On 24 April 2026, the Moroccan Medicines and Health Products Agency (AMMPS) announced publication of guidelines concerning the management and traceability of investigational medicines.

The guidelines address:

Importation of investigational medicines.

Monitoring and reconciliation.

Documentation requirements.

Storage and management.

Destruction of investigational products.

Responsibilities of relevant research participants and institutions.

These guidelines are particularly relevant when a tissue-engineering clinical investigation also involves investigational medicinal products. They should not automatically be treated as a complete regulatory code for engineered tissues themselves.

AMMPS

13. Major Legal Challenges in Tissue Engineering in Morocco

Despite the existing regulatory framework, several legal challenges remain.

A. Absence of a dedicated tissue-engineering statute

Morocco's laws regulate biomedical research, human tissue transplantation, pharmaceuticals and medical devices. However, they do not provide one comprehensive regulatory framework specifically addressing all tissue-engineered products.

B. Classification of engineered tissues

A major difficulty is determining whether a particular product should be regulated as:

A human tissue transplant.

A cell-therapy preparation.

A medicinal product.

A medical device.

A combination of biological and non-biological materials.

Different classifications may result in different authorization requirements.

C. Long-term safety monitoring

Engineered tissues may produce complications years after implantation. Morocco needs effective mechanisms for long-term patient monitoring, adverse-event reporting and treatment registries.

D. Commercial exploitation of biological materials

Commercial biotechnology companies may develop valuable products using donated human cells and tissues. Legal questions arise concerning donor consent, commercial interests, intellectual property and benefit-sharing.

E. Cross-border transportation

International transportation of biological samples creates concerns involving customs, biosafety, traceability, data protection and regulatory authorization.

F. Access and affordability

Advanced regenerative therapies may be expensive. Regulation must balance innovation with equitable access to treatment and protection against misleading medical advertising.

14. Recommendations for Strengthening Moroccan Regulation

Morocco could improve its tissue-engineering regulatory system through the following reforms:

1. Dedicated legislation: Introduce a specific legal framework for tissue-engineered products and advanced regenerative therapies.

2. Product classification: Establish clear criteria distinguishing cell therapies, engineered tissues, biomaterial scaffolds and medical devices.

3. Manufacturing standards: Introduce comprehensive quality standards covering cell isolation, processing, expansion, preservation and transportation.

4. Clinical trial transparency: Develop publicly accessible registries of authorized tissue-engineering clinical investigations.

5. Long-term monitoring: Establish mandatory post-treatment surveillance and adverse-event reporting for high-risk regenerative therapies.

6. Patient protection: Strengthen informed-consent requirements and compensation mechanisms.

7. Institutional supervision: Improve coordination among the Ministry of Health, AMMPS, regional ethics committees and the Human Organ Transplantation Advisory Council.

8. International cooperation: Harmonize relevant standards with WHO recommendations and appropriate international regulatory practices.

15. Conclusion

The regulation of tissue-engineering clinical applications in Morocco is based on a combination of biomedical research legislation, human tissue transplantation rules, pharmaceutical regulation, medical-device regulation and medical-practice requirements.

Law No. 16-98 provides an important foundation for human tissue donation and transplantation, while Law No. 28-13 establishes essential protections for participants in biomedical research. Law No. 17-04 and Law No. 84-12 provide additional regulatory frameworks where engineered products fall within their respective classifications.

The Ministry of Health's 2019 restriction on specified autologous cell-therapy activities represents a particularly important development because it requires authorization, institutional evaluation and informed patient consent.

Moroccan medical-liability principles also provide mechanisms for addressing injuries resulting from negligence, defective products and research-related harm.

Nevertheless, the absence of a comprehensive tissue-engineering-specific statute creates uncertainty concerning product classification, manufacturing standards, commercialization and long-term monitoring.

Ultimately, Morocco needs a specialized and scientifically responsive regulatory framework that protects patients while encouraging responsible innovation in regenerative medicine and tissue engineering.

16. Important Legal Authorities and References

17. Primary Research Sources

Moroccan Ministry of Health – Regulation of Medical Practices.

Law No. 28-13 – Biomedical Research Protection.

Moroccan Ministry of Health – Regulation of Health Products.

Ministry of Health – Cell Therapy Restrictions, 6 June 2019.

Moroccan Ministry of Health – Organ and Tissue Legislation.

General Secretariat of Government – Medical Practice and Clinic Authorization.

AMMPS – Investigational Medicine Traceability Guidelines, 24 April 2026.

Academic research note: For a dissertation or legal article, the most important distinction is between direct statutory requirements and legal principles applied by analogy. The Moroccan cases identified above concern medical liability generally; there is not sufficient verified published case law here to claim that Moroccan courts have already established a specific doctrine for tissue-engineered clinical products.